MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Health Care · MASH / liver disease therapeutics · Nasdaq
Madrigal is a commercial-stage biotech company exclusively focused on Rezdiffra, the first FDA-approved treatment for MASH with moderate-to-advanced fibrosis, now scaling US and EU commercialization.
What MADRIGAL PHARMACEUTICALS, INC. does
Madrigal Pharmaceuticals is a biopharmaceutical company focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company has commercialized Rezdiffra (resmetirom), its only FDA-approved product, for MASH patients with moderate to advanced liver fibrosis (F2-F3), and is pursuing regulatory approval in the European Union and expansion to broader MASH patient populations. The company is advancing clinical programs and developing additional pipeline candidates while building commercial infrastructure to drive Rezdiffra adoption.
Themes: ["MASH / NASH treatment","liver disease","metabolic disease","FXR agonists"]
Fundamentals
- Price$536.70 as of 2026-07-10 close
- Market cap$12.4B as of 2026-07-12
- 1-year return+70.6% as of 2026-07-10 close
- Net margin-27.3% as of 2026-07-12
- Gross margin+93.1% as of 2026-07-12
- ROE-50.1% as of 2026-07-12
- Debt / equity0.63 as of 2026-07-12
- Revenue growth (YoY)+256.8% as of 2026-07-12
- Beta-1.07 as of 2026-07-12
Key risks (from latest filing)
["Commercial execution risk: successful commercialization and market acceptance of Rezdiffra depends on physician, patient, and payer adoption in a competitive market","Regulatory risk: full approval in EU and expansion to broader MASH indications require positive outcomes trial results and regulatory approval","Competitive risk: intense competition in the MASH market and ability to maintain leadership position amid rapid market changes"]
Competitors & peers
- Intercept Pharmaceuticals (ICPT)
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Viking Therapeutics
Fundamentals: Finnhub, as of 2026-07-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.